RESUMEN
The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives whilst ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study was to transfer innovation from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve the understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will be: (i) to assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) to study the phenotypic characteristics and treatment over a 1-year period of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) to follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults.
Asunto(s)
Asma/epidemiología , Rinitis Alérgica/epidemiología , Factores de Edad , Anciano , Toma de Decisiones Clínicas , Comorbilidad , Evaluación Geriátrica , Humanos , Evaluación de Resultado en la Atención de Salud , Vigilancia de la PoblaciónRESUMEN
Workers exposed to a variety of wood dusts are known to experience work-related respiratory symptoms, including occupational asthma. There are, however, few reports of occupational asthma due to spruce wood. We present the case of a 31-year-old sawmill owner with severe asthma caused by exposure to spruce wood dust, who developed asthmatic symptoms after 2 years of working. Investigations included clinical examination, routine laboratory tests, spirometry, chest X-ray, total serum immunoglobulin E (IgE) and specific serum IgEs against various woods and other occupational allergens. Additionally, we monitored the peak expiratory flow rate (PEFR) and symptom score both at work and when off work. Specific serum IgE for spruce wood was detected (7.8 IU/ml). The results of PEFR and workplace symptom-score monitoring, coupled with an elevated eosinophil count in induced sputum, supported the diagnosis of occupational asthma. To our knowledge, this is the first well-documented case of occupational asthma induced by spruce wood dust. A type I immunological mechanism seems to be responsible.
Asunto(s)
Asma Ocupacional/etiología , Polvo , Exposición Profesional/efectos adversos , Picea/toxicidad , Madera/toxicidad , Adulto , Humanos , MasculinoRESUMEN
BACKGROUND: Interleukin-8 (IL-8) is a chemokine that causes chemotaxis of neutrophils, eosinophils and lymphocytes in vitro; however, its role as a chemoattractant in allergic inflammation is unclear. The objective of this study was to investigate the effect of nasal instillation of IL-8 on the influx of inflammatory cells. METHODS: Twelve patients suffering from seasonal allergic rhinitis hypersensitive to grass pollens, with average age 30.1 +/- 2.67 years were challenged both with diluent for IL-8 and IL-8 on a subsequent day, in two phases: before the pollen season (unprimed mucosa) and during the season (primed mucosa). The number of neutrophils, eosinophils and myeloperoxydase (MPO) levels in the nasal fluid collected after IL-8 or placebo challenge were determined. RESULTS: Challenge with IL-8 of primed nasal mucosa induced a significant influx of neutrophils (29 x 10(4) cells/ml at 0.5 h, 251 x 10(4) at 2 h and 334 x 10(4) at 3 h). Number of eosinophils in comparison with diluent challenge was not significant. There was no difference in MPO levels in the nasal lavage between IL-8 and diluent challenge of unprimed and primed mucosa. We did not find the relationship between MPO levels and the neutrophils number in the lavage (rank Spearman factor, RS = 0.258, P = 0.42). CONCLUSION: We have demonstrated that IL-8 causes influx of neutrophils but not eosinophils into nasal mucosa in vivo. MPO level seems to be of little value as a marker of neutrophil influx into nasal mucosa.
Asunto(s)
Quimiotaxis de Leucocito/efectos de los fármacos , Eosinófilos/efectos de los fármacos , Interleucina-8/farmacología , Neutrófilos/efectos de los fármacos , Rinitis Alérgica Estacional/inmunología , Administración Intranasal , Adulto , Recuento de Células , Eosinófilos/inmunología , Eosinófilos/patología , Femenino , Humanos , Interleucina-8/administración & dosificación , Masculino , Persona de Mediana Edad , Líquido del Lavado Nasal/química , Líquido del Lavado Nasal/citología , Mucosa Nasal/patología , Neutrófilos/inmunología , Neutrófilos/patología , Peroxidasa/análisis , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Rinitis Alérgica Estacional/patologíaRESUMEN
Macrolide antibiotics have a broad spectrum of activities against the common pathogens responsible for lower respiratory tract infections, therefore for over 40 years they have been useful in treatment of these diseases. The aim of this open randomised multicentre trial is to compare the efficacy and safety of spiramycin, one of the first macrolides, to clarithromycin, a new generation macrolide, in their normal condition of use in patient presenting with acute non-complicated lower respiratory tract infections. 55 adult non-hospitalised patients with clinical diagnosis of bronchitis or pneumonia were randomised to receive either spiramycin 3 MIU twice daily or clarithromycin 500 mg twice daily for 7 or 10 days. For clinical evaluable patients, successful outcome was noted for 96.15% (25/26) spiramycin-treated patients and 96.43% (27/28) clarithromycin-treated patients. Clinically significant improvement in signs and symptoms was comparable between treatment groups. 2 patients in the spiramycin group (7.69%) and 3 in clarithromycin group (10.71%) complained of adverse events which severity was mild or moderate and did not require interruption of conducting antibioticotherapy. Efficacy and safety analysis showed that the two macrolides were equally effective and well-tolerated, at the given doses, for the treatment of lower respiratory tract infections and may play important role in out-patient therapy of these diseases.